AR014733A1 - El uso de una molecula de acido nucleico que codifica una glicosidasa conjuntamente con un substrato de glicosido cianogenico no toxico, que despuesde la degradacion por la glicosidasa produce cianuro de hidrogeno y un estuche para el tratamiento de tumores cerebrales que permite la administracion p - Google Patents

El uso de una molecula de acido nucleico que codifica una glicosidasa conjuntamente con un substrato de glicosido cianogenico no toxico, que despuesde la degradacion por la glicosidasa produce cianuro de hidrogeno y un estuche para el tratamiento de tumores cerebrales que permite la administracion p

Info

Publication number
AR014733A1
AR014733A1 ARP990101152A ARP990101152A AR014733A1 AR 014733 A1 AR014733 A1 AR 014733A1 AR P990101152 A ARP990101152 A AR P990101152A AR P990101152 A ARP990101152 A AR P990101152A AR 014733 A1 AR014733 A1 AR 014733A1
Authority
AR
Argentina
Prior art keywords
glycosidase
nucleic acid
substrate
degradation
conjunction
Prior art date
Application number
ARP990101152A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR014733A1 publication Critical patent/AR014733A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

El uso de una molécula de ácido nucleico que codifica una glicosidasa conjuntamente con un substrato de glicosido cianogénico no toxico, que despuésde la degradacion por glicosidasa produce cianuro de hidrogeno, para la preparacion de un medicamento destinado a la administacion por separado de doscomponentes interactuantes en el tratamiento de tumores cerebrales en animales o seres humanos. El ADN codifica preferiblemente para la linamarasa, y elsubstrato es preferiblemente la linamarina. El ADN es llevado por un vector virico o un plásmido. Un estuche para el tratamiento de tumores cerebrales quees apropiado para la administracion por separado de la molécula de ácido nucleico y del sustrato de glicosido cianogénico no toxico, el cual en unprimer recipiente contiene la preparacion con la molécula de ácido nucleico que codifica la glicosidasa, y en un segundo recipiente contiene el sustratocianogénico. Desarrollo de un sistema alternativo de gen suicida para lapreparacion de un medicamento destinado al tratamiento de tumores cerebrales,en particular de los del tipo maligno tales como el glioblastoma.
ARP990101152A 1998-03-17 1999-03-17 El uso de una molecula de acido nucleico que codifica una glicosidasa conjuntamente con un substrato de glicosido cianogenico no toxico, que despuesde la degradacion por la glicosidasa produce cianuro de hidrogeno y un estuche para el tratamiento de tumores cerebrales que permite la administracion p AR014733A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98104756A EP0943680A1 (en) 1998-03-17 1998-03-17 Suicide gene therapy system for the treatment of brain tumours

Publications (1)

Publication Number Publication Date
AR014733A1 true AR014733A1 (es) 2001-03-28

Family

ID=8231598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101152A AR014733A1 (es) 1998-03-17 1999-03-17 El uso de una molecula de acido nucleico que codifica una glicosidasa conjuntamente con un substrato de glicosido cianogenico no toxico, que despuesde la degradacion por la glicosidasa produce cianuro de hidrogeno y un estuche para el tratamiento de tumores cerebrales que permite la administracion p

Country Status (8)

Country Link
EP (2) EP0943680A1 (es)
JP (1) JP2002506885A (es)
AR (1) AR014733A1 (es)
AU (1) AU3329999A (es)
CA (1) CA2323897A1 (es)
CO (1) CO5080825A1 (es)
WO (1) WO1999047653A1 (es)
ZA (1) ZA992063B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304276B1 (es) * 2005-12-23 2009-07-28 Universidad Autonoma De Madrid Uam Efecto sinergico entre un sistema cianogenico y otro inductor oxidativo para el tratamiento de tumores.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001641D0 (en) * 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
WO1994028127A1 (en) * 1993-05-24 1994-12-08 Imperial Cancer Research Technology Limited Cancer treatment
JPH09248182A (ja) * 1996-03-15 1997-09-22 Oyo Seikagaku Kenkyusho プラスミド包埋多重膜リポソーム
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy

Also Published As

Publication number Publication date
JP2002506885A (ja) 2002-03-05
EP0943680A1 (en) 1999-09-22
ZA992063B (en) 1999-09-17
CA2323897A1 (en) 1999-09-23
WO1999047653A1 (en) 1999-09-23
EP1062328A1 (en) 2000-12-27
CO5080825A1 (es) 2001-09-25
AU3329999A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
Gao et al. Intra/extracellular lactic acid exhaustion for synergistic metabolic therapy and immunotherapy of tumors
US9938525B2 (en) Compositions and methods for selective delivery of oligonucleotide molecules to cell types
WO2004084950A3 (en) Cell targeting methods and compositions
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
SI2579900T1 (en) VECTORS AND DIAGNOSES FOR TREATMENT OF DISEASES
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
AU6808001A (en) Glutamic acid decarboxylase (gad) based delivery systems
BR0009693A (pt) Mistura para a preparação de espumas duras de poliuretano
MX2020009512A (es) Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados.
Li et al. Arginine‐rich membrane‐permeable peptides are seriously toxic
Brennen et al. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)‐activated prodrug in murine xenograft models of human cancer
Pozsgai et al. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma
Wang et al. Integrated treatment of aqueous extract of Solanum nigrum‐potentiated cisplatin‐and doxorubicin‐induced cytotoxicity in human hepatocellular carcinoma cells
BR0111869A (pt) Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
Nashed et al. Cancer-induced oxidative stress and pain
AR014733A1 (es) El uso de una molecula de acido nucleico que codifica una glicosidasa conjuntamente con un substrato de glicosido cianogenico no toxico, que despuesde la degradacion por la glicosidasa produce cianuro de hidrogeno y un estuche para el tratamiento de tumores cerebrales que permite la administracion p
Yu et al. DNAzyme‐Mediated Cascade Nanoreactor for Cuproptosis‐Promoted Pancreatic Cancer Synergistic Therapy
Nair et al. Emulsomes: A novel liposomal formulation for sustained drug delivery
Taniai et al. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells
Sari et al. Spinal serotonin and 5HT6 receptor levels during development of neuropathy and influence of blockade of these receptors on thermal hyperalgesia in diabetic mice
Biscans et al. Direct Synthesis of Partially Modified 2′‐O‐Pivaloyloxymethyl RNAs by a Base‐Labile Protecting Group Strategy and their Potential for Prodrug‐Based Gene‐Silencing Applications